Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
2(40.0%)
Phase 2
2(40.0%)
Phase 3
1(20.0%)
5Total
Phase 4(2)
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06667999Phase 4Recruiting

The Intensive Care Platform Trial

Role: lead

NCT02111161Phase 2Completed

Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial

Role: lead

NCT01532544Phase 2Terminated

Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis

Role: collaborator

NCT02079402Phase 4Completed

Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care

Role: lead

NCT00962156Phase 3Completed

Scandinavian Starch for Severe Sepsis/Septic Shock Trial

Role: lead

All 5 trials loaded